Home / India News / Health and Pharmaceuticals
INDIA · HEALTH POLICY · MEDICINE PRICES · NOVEMBER 11137 Anti-Cancer Drugs: Revised NPPA Prices Take Effect, 1,031 Formulations Cut
Revised NPPA prices for 137 identified anti-cancer drugs took effect on November 9. The government says 1,031 formulations have lower MRPs, with savings varying by medicine and brand.
New Delhi, November 11, 2026: Revised maximum retail prices for a large group of anti-cancer medicines have taken effect across India, following the National Pharmaceutical Pricing Authority's decision to cap trade margins on 137 identified non-scheduled cancer drugs. The Department of Pharmaceuticals said on November 7 that 76 pharmaceutical companies had submitted revised prices for 1,225 formulations covering 121 of the 137 identified drugs.
Of those formulations, 1,031 had reported MRP reductions. The government said 600 brands showed reductions of more than 50 per cent and the steepest reported reduction was 96.45 per cent. It estimated that the changes could save consumers about ₹3,502.31 crore a year. That figure is a government estimate for the market as a whole, not a promise that every patient or every prescription will become cheaper by the same amount.
What changed from November 9?
The revised prices became effective on November 9, after the NPPA used the Trade Margin Rationalisation mechanism under Paragraph 19 of the Drugs (Prices Control) Order, 2013. The measure applies to 137 identified non-scheduled anti-cancer drugs. The authority's objective is to reduce excessive mark-ups between the first point of sale and the price charged to patients, while keeping the permitted trade margin within the notified limit.
The distinction between a drug and a formulation matters. A single medicine can be sold by several companies under different brand names, strengths, pack sizes and dosage forms. The government's November 7 update counted 1,225 formulations, but the revised price a patient sees depends on the exact product prescribed and stocked by the hospital or pharmacy.
Examples in the government's revised price list
The PIB release listed several examples to show how sharply individual brand MRPs can change. The listed price for Zydus Lifesciences' Bryxta, a 100 mg bevacizumab injection, moved from ₹25,995 to ₹3,318. RPG Life Sciences' Palbopro 125 mg capsule, containing palbociclib, moved from ₹40,421.33 to ₹2,720. Arvincare Pharma's Abirone 250 mg tablet, containing abiraterone acetate, moved from ₹41,250 to ₹3,218.23.
Another example is Lupin's Lupiher 2, a 420 mg pertuzumab injection, for which the listed MRP changed from ₹83,520 to ₹37,358.35. These are brand-specific entries in the official list. They should not be treated as the price of every formulation containing the same active ingredient, and they do not replace a doctor's prescription or a hospital's treatment plan.
Economic Times and NDTV Profit also reported the revised brand list and the scale of reductions. Their reports broadly match the Department of Pharmaceuticals' figures, while the government release remains the primary source for the official count and its estimated annual savings.
How patients and caregivers can check the correct price
Patients should compare the exact brand, strength, dosage form and pack size on the prescription and bill with the revised MRP list. A price change for one brand does not automatically mean that another brand, imported product or different strength has the same MRP. Hospitals, pharmacies, retailers and dealers are required to display revised price lists on their premises and websites.
The government says consumers can check applicable prices through the NPPA website and the Pharma Sahi Daam mobile application. If a retailer or hospital appears to be charging above the revised MRP, the Department of Pharmaceuticals has listed the NPPA monitoring email, monitoring-nppa@gov.in, and helpline 1800-11-1255 for complaints. Keep the bill and the medicine packaging when raising a price complaint.
What the price change does not mean
The policy does not mean every cancer medicine in India has become cheaper, nor does it mean that every patient will see the same percentage reduction in total treatment costs. The government said 10 to 15 of the identified drugs had not yet been launched in India; the margin-rationalisation rules will apply to them if and when they enter the market. Some formulations may already have been priced below the recalculated maximum and may therefore not show the same kind of reduction.
Actual out-of-pocket spending also depends on the prescribed treatment regimen, frequency of administration, hospital charges, diagnostics, supportive medicines, insurance coverage and whether the patient receives a particular brand. Patients should not stop, switch or alter a cancer medicine because of a price list. Any substitution or change in treatment must be discussed with the treating oncologist.
What happens next?
State drug controllers are responsible for monitoring compliance among manufacturers, dealers, retailers, hospitals and medical institutions. The Department of Pharmaceuticals has also said manufacturers must maintain supply levels for the notified formulations, a safeguard intended to prevent price regulation from creating avoidable shortages. The NPPA can update its price information as companies submit further revisions and as additional identified medicines enter the Indian market.
For patients, the practical step is simple: check the current MRP of the exact medicine before payment, ask the hospital pharmacy for its updated list, and retain the bill. The headline percentage is useful context, but the price printed for the specific formulation is what matters at the counter.
Frequently asked questions
When did the revised anti-cancer medicine prices take effect?
The revised prices took effect on November 9, 2026.
Do all 137 medicines already have revised prices?
No. The November 7 government update said revised MRPs had been reported for 1,225 formulations covering 121 drugs. It also said 10 to 15 identified drugs had not yet launched in India.
Where can patients check a medicine's revised MRP?
Patients can check the NPPA website and the Pharma Sahi Daam app, and should compare the exact brand, strength and pack size.
What if a pharmacy charges more than the revised MRP?
Keep the bill and report the issue to NPPA through monitoring-nppa@gov.in or its 1800-11-1255 helpline.
- Department of Pharmaceuticals / PIB: Revised prices of anti-cancer medicines, November 7, 2026
- The Economic Times: Cancer drug prices to fall by up to 96%; estimated annual savings
- NDTV Profit: NPPA revises prices for 543 anti-cancer drug brands
- National Pharmaceutical Pricing Authority
Editorial note: This report is written in original language from the linked primary record or official release and independent reporting. Confirmed directions are separated from estimates, proposed measures and implementation steps. The accompanying illustration is conceptual and is not evidence of a specific person, place or incident.
Related coverage: Latest India news · Rajasthan news · Business and economy · Education updates